Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

ABSTRACT:

Background

Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity.

Methods

In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both). The primary end point was progression-free survival. Secondary end points included survival, response rate, and safety. A preplan

SUBMITTER: Baselga J 

PROVIDER: S-EPMC5705195 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature